CBD Shows Potential for Reducing Anxiety in Women with Advanced Breast Cancer
• A phase II trial explored CBD's effect on anxiety in women with advanced breast cancer before scans, a common trigger for anxiety.
• While the primary endpoint of significant anxiety reduction wasn't met, patients reported lower anxiety levels 2-4 hours after CBD ingestion.
• The study suggests CBD is safe for anxiety management in this population, warranting further investigation into its anxiolytic properties.
• Researchers emphasize the need for larger trials to validate CBD's efficacy and explore its role in cancer-related anxiety treatment.
MOST Trial: Anti-Clotting Drugs Fail to Improve Outcomes in Stroke Patients
• The MOST trial investigated the efficacy of adding argatroban or eptifibatide to intravenous thrombolysis for stroke patients to prevent further clots.
• Results indicated that neither argatroban nor eptifibatide improved patient outcomes and had a less than 1% probability of being helpful.
• The study, conducted across 57 U.S. sites, found that these drugs were linked to greater incidences of disability and mortality within three months post-treatment.
• Researchers emphasize that negative trials like MOST are crucial for informing future research and developing new anticoagulant treatments for stroke.
© Copyright 2025. All Rights Reserved by MedPath